CPP-115 explained
| Width: | 180 |
| Legal Status: | Investigational |
| Cas Number: | 640897-20-7 |
| Pubchem: | 9794014 |
| Unii: | 5TD9324Z2U |
| Iupac Name: | (1S,3S)-3-Amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid |
| C: | 7 |
| H: | 9 |
| F: | 2 |
| N: | 1 |
| O: | 2 |
CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction,[1] infantile spasms,[2] [3] and Tourette syndrome.[4]
CPP-115 is a GABA aminotransferase (GABA-AT) inactivator.[1]
History
CPP-115 was discovered in the research laboratory of Richard B. Silverman, for which he received the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances.[5] It was licensed to Catalyst Pharmaceuticals for development in 2009.[6] [7]
CPP-115 has been granted orphan drug status for the treatment of infantile spasms by the FDA and for the treatment of West syndrome by the European Commission.[8]
As of 2022, CPP-115 is in Phase II clinical trials for Tourette syndrome.[4]
Notes and References
- Pan Y, Gerasimov MR, Kvist T, Wellendorph P, Madsen KK, Pera E, Lee H, Schousboe A, Chebib M, Bräuner-Osborne H, Craft CM, Brodie JD, Schiffer WK, Dewey SL, Miller SR, Silverman RB . 6 . (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction . Journal of Medicinal Chemistry . 55 . 1 . 357–366 . January 2012 . 22128851 . 3257419 . 10.1021/jm201231w .
- Web site: Epilepsy Pipeline Tracker: CPP-115 . epilepsy.com .
- Doumlele K, Conway E, Hedlund J, Tolete P, Devinsky O . A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms . Epilepsy & Behavior Case Reports . 6 . 67–69 . 2016 . 27668180 . 5024311 . 10.1016/j.ebcr.2016.08.002 .
- Web site: CPP-115 . Adis Insight .
- Silverman RB . The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms . Journal of Medicinal Chemistry . 55 . 2 . 567–575 . January 2012 . 22168767 . 3266980 . 10.1021/jm201650r .
- Hawker DD, Silverman RB . Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase . Bioorganic & Medicinal Chemistry . 20 . 19 . 5763–5773 . October 2012 . 22944334 . 3448830 . 10.1016/j.bmc.2012.08.009 .
- Web site: Bandell B . Catalyst Pharmaceutical signs licensing deal with Northwestern . South Florida Business Journal . August 31, 2009.
- Catalyst Pharmaceuticals Expands Commercial Leadership Team . Catalyst Pharmaceuticals .
